<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6357">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01655303</url>
  </required_header>
  <id_info>
    <org_study_id>16057</org_study_id>
    <nct_id>NCT01655303</nct_id>
  </id_info>
  <brief_title>Rate Control in Atrial Fibrillation</brief_title>
  <acronym>-</acronym>
  <official_title>Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rate control in atrial fibrillation is a usual battle in emergency departments. Oral
      medications have a natural superiority to intravenous ones because they are easy-to-use and
      decrease the workload in busy emergency departments.

      This study wants to find an effective oral medication for rate control in rapid ventricular
      response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are
      compared in patients with a stable hemodynamic status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate less than 100 per minute</measure>
    <time_frame>In 1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ventricular rate less than 100 per minute after 1 hour of per oral medication administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drugs adverse effects</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Drugs adverse effects seen in patients in 2 hours after per oral medication administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstability in hemodynamic</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hemodynamic instability (systolic blood pressure less than 90 mmHg, loss of consciousness, pulmonary edema, chest pain)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Rapid Ventricular Response Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Metoprolol Per Oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Metoprolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Verapamil Per Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Propranolol Per Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diltiazem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg Diltiazem Per Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <arm_group_label>Metoprolol Per Oral</arm_group_label>
    <other_name>Metoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <arm_group_label>Diltiazem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than 18 years old

          -  Stability in hemodynamic

        Exclusion Criteria:

          -  Systolic blood pressure less than 90 mm Hg

          -  Altered mental status attributable to rapid ventricular response atrial fibrillation

          -  Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation

          -  Chest pain attributable to rapid ventricular response atrial fibrillation

          -  Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem

          -  History of asthma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rasoul-e-Akram Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14436151</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 30, 2012</lastchanged_date>
  <firstreceived_date>July 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
